Abuse-Deterrent Lipid Matrix Soft Capsule for Opioid Formulations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for abuse deterrent pharmaceutical compositions that prevent extraction and misuse of prescription medications, particularly opioids, by minimizing tampering and 'dose dumping' through controlled release matrices resistant to boiling conditions.
Innovation Solution
The development of an abuse deterrent controlled release oral pharmaceutical composition comprising a tamper-resistant matrix made of lipid or lipophilic vehicles, organogelators, hydrophilic polymers, and antioxidants, encapsulated in a soft capsule shell, which slows the release of active pharmaceutical ingredients and resists extraction under boiling conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a controlled release matrix is used to prevent abuse and dose dumping, then resistance to tampering and extraction is improved, but the complexity of the formulation increases
Solution Approach 1:
The patent employs a composite matrix formulation combining multiple materials (hydrophilic polymers, lipids, organogelators, and antioxidants) to achieve both abuse deterrence and controlled release. This composite approach allows the single dosage form to simultaneously resist tampering, prevent dose dumping, and provide sustained drug release, thereby addressing multiple requirements without proportionally increasing complexity.
2Reliability
If a tamper-resistant controlled release matrix is used to prevent extraction of active ingredients, then abuse deterrence is improved, but the manufacturing process complexity increases
Solution Approach 1:
The patent utilizes parameter changes in the matrix materials, particularly the gelation temperature of organogelators and the phase transition properties of lipids, to create a formulation that is resistant to extraction and tampering. These parameter-based approaches allow for abuse deterrence through inherent material properties rather than complex manufacturing processes, simplifying production while maintaining high reliability against abuse.
3Object-affected harmful factors
If a multi-component matrix formulation is used to resist boiling conditions and prevent dose dumping, then safety is improved, but the number of ingredients and formulation complexity increases
Solution Approach 1:
The patent introduces organogelators as intermediary substances that form gel structures within the matrix, acting as mediators between the lipid components and the active pharmaceutical ingredient. These gel networks provide structural integrity under boiling conditions and control drug release, enabling the formulation to resist dose dumping while using a manageable number of carefully selected ingredients rather than excessive components.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively prevents rapid release of active ingredients, reducing the risk of misuse and maintaining therapeutic efficacy while minimizing opioid-induced bowel dysfunction.
Implementation Method 1
the organogelator forms a gel at a temperature of about 90° C. to about 120° C.
Implementation Method 2
the lipid or lipophilic vehicle comprises about 30% to about 85% of the total matrix mass
Data Source
AI summary
Described herein are abuse deterrent controlled release oral pharmaceutical compositions comprising and methods for making the same. In particular, an abuse deterrent controlled release oral pharmaceutical composition comprising a soft capsule and an abuse deterrent controlled release matrix comprising an active pharmaceutical ingredient are described.